Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects

• Drug: Sertraline
  
  Multiple doses of sertraline for 14 days
  Other Name: active drug
• Drug: Moxifloxacin
  
  A single dose of 400 mg Moxifloxacin
  Other Name: Positive control
• Drug: Drug - Placebo
  
  Placebo administered for 14 days
  Other Name: Placebo control

• Experimental: Sertraline
  
  Maximum dose of 400 mg/day (200 mg BID given at approximately 12 hours apart) sertraline, dose titrated from a starting single dose (QD) of 50 mg in the morning on Day 1 followed by BID doses administered on Days 2 through 14 (Day 14 morning dose only) will be administered
  Intervention: Drug: Sertraline
• Active Comparator: Moxifloxacin
  
  400 mg single dose of moxifloxacin (Avelox®) administered on Day 14
  Intervention: Drug: Moxifloxacin
• Placebo Comparator: Drug - Placebo
  
  placebo - placebo administered on Days 1 through 14
  Intervention: Drug: Drug - Placebo

Inclusion Criteria:

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).

Risk factors for QT prolongation or torsades de pointes